[HTML] sciencedirect.com

[HTML][HTML] European Association of Nuclear Medicine Focus 5: consensus on molecular imaging and theranostics in prostate cancer

DE Oprea-Lager, S MacLennan, A Bjartell, A Briganti… - European Urology, 2024 - Elsevier
Abstract Background In prostate cancer (PCa), questions remain on indications for prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) imaging and …
被引用次数：5 相关文章
[PDF] stichtingduos.nl

[PDF][PDF] European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

DE Oprea-Lager, S MacLennan, A Bjartell, A Briganti… - 2023 - stichtingduos.nl
Abstract Background: In prostate cancer (PCa), questions remain on indications for
prostatespecific membrane antigen (PSMA) positron emission tomography (PET) imaging …

European association of nuclear medicine focus 5: Consensus on molecular imaging and theranostics in prostate cancer

DE Oprea-Lager, S MacLennan, A Bjartell… - European …, 2024 - devnauka.pib-nio.pl
BACKGROUND: In prostate cancer (PCa), questions remain on indications for prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) imaging and …

European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

DE Oprea-Lager, S MacLennan, A Bjartell… - European …, 2024 - portal.research.lu.se
Background: In prostate cancer (PCa), questions remain on indications for prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA …

European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

DE Oprea-Lager, S Maclennan, A Bjartell… - EUROPEAN …, 2023 - iris.uniroma1.it
Background: In prostate cancer (PCa), questions remain on indications for prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA …
[PDF] uros.pl

[PDF][PDF] European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

DE Oprea-Lager, S MacLennan, A Bjartell, A Briganti… - 2023 - uros.pl
Abstract Background: In prostate cancer (PCa), questions remain on indications for
prostatespecific membrane antigen (PSMA) positron emission tomography (PET) imaging …

European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

DE Oprea-Lager, S MacLennan, A Bjartell… - European …, 2024 - zora.uzh.ch
BACKGROUND In prostate cancer (PCa), questions remain on indications for prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) imaging and …

European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

DE Oprea-Lager, S MacLennan, A Bjartell… - European …, 2024 - abdn.elsevierpure.com
BACKGROUND: In prostate cancer (PCa), questions remain on indications for prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) imaging and …
[PDF] qub.ac.uk

[PDF][PDF] European Association of Nuclear Medicine Focus 5: consensus on molecular imaging and theranostics in prostate cancer

DE Oprea-Lager, S MacLennan, A Bjartell… - EUROPEAN …, 2024 - pureadmin.qub.ac.uk
Abstract Background: In prostate cancer (PCa), questions remain on indications for
prostatespecific membrane antigen (PSMA) positron emission tomography (PET) imaging …

European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.

DE Oprea-Lager, S MacLennan, A Bjartell… - European …, 2023 - europepmc.org
Background In prostate cancer (PCa), questions remain on indications for prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA …